Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival

Annals of Oncology

Volumn 25, Issue 7, 2014, Pages 1253-1255

  Helleday, T ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BORTEZOMIB; BRCA1 PROTEIN; BRCA2 PROTEIN; CRIZOTINIB; ENZYME; MTH1 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM COMPLEX; UNCLASSIFIED DRUG; VEMURAFENIB; 8-OXODGTPASE; PHOSPHATASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

B RAF GENE; CANCER RESISTANCE; CANCER SURVIVAL; EDITORIAL; GENE MUTATION; GENE TARGETING; GENOTYPE; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; CELL SURVIVAL; ENZYMOLOGY; GENETICS; NEOPLASMS; PATHOLOGY; PHENOTYPE;

CELL SURVIVAL; DNA REPAIR ENZYMES; HUMANS; NEOPLASMS; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES;

EID: 84903751068     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu158     Document Type: Editorial

References (14)

1. Huber KV, Salah E, Radic B et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 2014; 508: 222-227.
2. Gad H, Koolmeister T, Jemth AS et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature 2014; 508: 215-221.
3. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and nononcogene addiction. Cell 2009; 136: 823-837.
4. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
5. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
6. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004; 6: 313-319.
7. Roccaro AM, Hideshima T, Richardson PG et al. Bortezomib as an antitumor agent. Curr Pharm Biotechnol 2006; 7: 441-448.
8. Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol 2011; 5: 368-373.
9. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 2005; 434: 913-917.
10. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
11. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382-1392.
12. Sakai W, Swisher EM, Karlan BY et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120.
13. Bunting SF, Callen E, Wong N et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141: 243-254.
14. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011; 12: 852-861.